UNSPSC 51294402: Adatanserin

This classification denotes a serotonin antagonist with the molecular formula C21H31N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W5U6WQM26H, chemically known as tricyclo(3.3.1.1(3,7))decane-1-carboxamide, n-(2-(4-(2-pyrimidinyl)-1-piperazinyl)ethyl)- but generally known as adatanserin, which bears US NIH Compound Identifier 130918. Adatanserin comes in base and hydrochloride form. European Medicines Agency schedules Adatanserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05263MIG.

UNSPSC 51294402 Adatanserin, a Commodity code, does not align with the state and local procurement activity tagged under it. The three recent opportunities posted under this code solicit naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and OTC products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). None of these procurements involve adatanserin, a serotonin antagonist pharmaceutical compound. The code shows little relevant recent activity for its nominal scope.

The mismatch between the code's chemical-specific naming and the actual work being sourced suggests these opportunities may be miscoded or the code may be used as a catch-all for pharmaceutical procurement across diverse product categories. Issuing bodies include state health agencies, county health departments, and multistate cooperative purchasing vehicles operating across participating states. Geographic activity spans Florida, Texas, and Minnesota. The representative opportunities include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023), the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (due April 3, 2026), and MMCAP's RFP for generic pharmaceuticals and OTC products (due March 26, 2026). Vendors pursuing this code should verify actual commodity alignment before bidding, as the nominal code definition does not match the pharmaceutical procurement landscape currently active under this number.